-
1 Comment
Global Cord Blood Corporation is currently in a long term uptrend where the price is trading 17.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
Global Cord Blood Corporation's total revenue sank by 13.1% to $291M since the same quarter in the previous year.
Its net income has dropped by 19.6% to $117M since the same quarter in the previous year.
Finally, its free cash flow grew by inf% to $624M since the same quarter in the previous year.
Based on the above factors, Global Cord Blood Corporation gets an overall score of 3/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for CO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
